ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

17 links0 made here, not in the record36 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05725200Study to InvestigateOutcome of IndividualizedTreatment in Patients WithMetastatic ColorectalCancerOslo University HospitalPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSColorectal NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSAlectinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCetuximabIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCrizotinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDasatinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEverolimusIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEncorafenibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedGemcitabineIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIdelalisibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLarotrectinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedMethotrexateIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPalbociclibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPanobinostatIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundTrastuzumabIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTalazoparibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedVenetoclaxIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Alectinib

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Alectinib”the record gives no role
→judged=agrees=agrees
How the 3 judgments split100%of judgments with a known value say Tested
Tested · 3

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1AlectinibClaude Opus 5.5TestedReplaced
Nov 1CetuximabClaude Opus 5.5TestedCurrent
Nov 1CrizotinibClaude Opus 5.5TestedCurrent
Nov 1DasatinibClaude Opus 5.5TestedCurrent
Nov 1EverolimusClaude Opus 5.5TestedCurrent
Nov 1EncorafenibClaude Opus 5.5TestedCurrent
Nov 1GemcitabineClaude Opus 5.5TestedCurrent
Nov 1IdelalisibClaude Opus 5.5TestedCurrent
Nov 1LarotrectinibClaude Opus 5.5TestedCurrent
Nov 1MethotrexateClaude Opus 5.5TestedCurrent
Nov 1PalbociclibClaude Opus 5.5TestedReplaced
Nov 1PanobinostatClaude Opus 5.5TestedCurrent
Nov 1PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 1TrastuzumabClaude Opus 5.5TestedReplaced
Nov 1TalazoparibClaude Opus 5.5TestedCurrent
Nov 1VenetoclaxClaude Opus 5.5TestedCurrent
Nov 2AlectinibClaude Opus 5.5TestedCurrent
Nov 2PalbociclibClaude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5TestedCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18AlectinibRule based · role ruleTestedAgrees
Nov 18CetuximabRule based · role ruleTestedAgrees
Nov 18CrizotinibRule based · role ruleTestedAgrees
Nov 18DasatinibRule based · role ruleTestedAgrees
Nov 18EverolimusRule based · role ruleTestedAgrees
Nov 18EncorafenibRule based · role ruleTestedAgrees
Nov 18GemcitabineRule based · role ruleTestedAgrees
Nov 18IdelalisibRule based · role ruleTestedAgrees
Nov 18LarotrectinibRule based · role ruleTestedAgrees
Nov 18MethotrexateRule based · role ruleTestedAgrees
Nov 18PalbociclibRule based · role ruleTestedAgrees
Nov 18PanobinostatRule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleTestedOverridden
Nov 18TrastuzumabRule based · role ruleTestedAgrees
Nov 18TalazoparibRule based · role ruleTestedAgrees
Nov 18VenetoclaxRule based · role ruleTestedAgrees
As of nowColorectal NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.